# Noopur S Raje

## List of Publications by Citations



| | | | |
|---|---|---|---|
| 334 papers | 9,901 citations | 48 h-index | 95 g-index |
| 364 ext. papers | 12,346 ext. citations | 4.8 avg, IF | 6.13 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 334 | Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. *Blood*, **2010**, 116, 679-86 | 2.2 | 680 |
| 333 | Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. *New England Journal of Medicine*, **2019**, 380, 1726-1737 | 59.2 | 672 |
| 332 | Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. *Blood*, **2012**, 119, 2579-89 | 2.2 | 458 |
| 331 | Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. *Blood*, **2009**, 114, 371-9 | 2.2 | 331 |
| 330 | Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. *New England Journal of Medicine*, **2021**, 384, 705-716 | 59.2 | 287 |
| 329 | Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. *Blood*, **2013**, 121, 2975-87 | 2.2 | 268 |
| 328 | Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement. *Journal of Clinical Oncology*, **2015**, 33, 657-64 | 2.2 | 262 |
| 327 | International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. *Journal of Clinical Oncology*, **2013**, 31, 2347-57 | 2.2 | 245 |
| 326 | Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. *Lancet Oncology, The*, **2018**, 19, 370-381 | 21.7 | 216 |
| 325 | Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma. *Clinical Cancer Research*, **2015**, 21, 4607-18 | 12.9 | 214 |
| 324 | Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study. *JAMA Oncology*, **2018**, 4, 384-388 | 13.4 | 191 |
| 323 | Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. *Cancer Research*, **2006**, 66, 6675-82 | 10.1 | 187 |
| 322 | Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice. *Journal of Clinical Investigation*, **2008**, 118, 491-504 | 15.9 | 183 |
| 321 | Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 5124-9 | 11.5 | 182 |
| 320 | Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. *Blood*, **2004**, 104, 4188-93 | 2.2 | 167 |
| 319 | International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. *Lancet Oncology, The*, **2019**, 20, e302-e312 | 21.7 | 166 |
| 318 | Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma. *Blood*, **2005**, 106, 1042-7 | 2.2 | 152 |

| | | | |
|---|---|---|---|
| 317 | Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma. *Clinical Cancer Research*, **2017**, 23, 3307-3315 | 12.9 | 148 |
| 316 | Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2017**, 15, 230-269 | 7.3 | 142 |
| 315 | Advances in the biology and treatment of bone disease in multiple myeloma. *Clinical Cancer Research*, **2011**, 17, 1278-86 | 12.9 | 140 |
| 314 | Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial. *Lancet Oncology, The*, **2016**, 17, 1569-1578 | 21.7 | 133 |
| 313 | MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts. *Blood*, **2007**, 110, 3744-52 | 2.2 | 132 |
| 312 | Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T). *Journal of the American College of Cardiology*, **2019**, 74, 3099-3108 | 15.1 | 123 |
| 311 | RAFTK/PYK2-dependent and -independent apoptosis in multiple myeloma cells. *Oncogene*, **1999**, 18, 6733-40 | 9.2 | 121 |
| 310 | Cyclin dependent kinases in cancer: potential for therapeutic intervention. *Cancer Biology and Therapy*, **2012**, 13, 451-7 | 4.6 | 116 |
| 309 | Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model. *Clinical Cancer Research*, **2007**, 13, 5903-9 | 12.9 | 116 |
| 308 | Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw. *Clinical Cancer Research*, **2008**, 14, 2387-95 | 12.9 | 114 |
| 307 | Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial. *Journal of Clinical Oncology*, **2011**, 29, 4243-9 | 2.2 | 107 |
| 306 | Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline. *Journal of Clinical Oncology*, **2019**, 37, 1228-1263 | 2.2 | 104 |
| 305 | Genetic interrogation of circulating multiple myeloma cells at single-cell resolution. *Science Translational Medicine*, **2016**, 8, 363ra147 | 17.5 | 93 |
| 304 | Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia. *Journal of Clinical Oncology*, **2018**, 36, 2755-2761 | 2.2 | 91 |
| 303 | Targeting Cyclin-Dependent Kinases and Cell Cycle Progression in Human Cancers. *Seminars in Oncology*, **2015**, 42, 788-800 | 5.5 | 81 |
| 302 | Targeting the metabolic plasticity of multiple myeloma with FDA-approved ritonavir and metformin. *Clinical Cancer Research*, **2015**, 21, 1161-71 | 12.9 | 77 |
| 301 | Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better?. *Leukemia*, **2020**, 34, 21-34 | 10.7 | 74 |
| 300 | NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2019**, 17, 1154-1165 | 7.3 | 73 |

| | | | |
|---|---|---|---|
| 299 | Regulation of Sclerostin Expression in Multiple Myeloma by Dkk-1: A Potential Therapeutic Strategy for Myeloma Bone Disease. *Journal of Bone and Mineral Research*, **2016**, 31, 1225-34 | 6.3 | 72 |
| 298 | A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. *British Journal of Haematology*, **2018**, 182, 222-230 | 4.5 | 70 |
| 297 | Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update. *Journal of Clinical Oncology*, **2018**, 36, 812-818 | 2.2 | 69 |
| 296 | Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results.. *Journal of Clinical Oncology*, **2020**, 38, 8503-8503 | 2.2 | 68 |
| 295 | A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma. *Blood*, **2019**, 134, 123-133 | 2.2 | 65 |
| 294 | Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma. *British Journal of Haematology*, **2004**, 125, 343-52 | 4.5 | 64 |
| 293 | The KDM3A-KLF2-IRF4 axis maintains myeloma cell survival. *Nature Communications*, **2016**, 7, 10258 | 17.4 | 61 |
| 292 | Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors. *Leukemia*, **2018**, 32, 1932-1947 | 10.7 | 59 |
| 291 | In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma. *Bone*, **2013**, 53, 487-96 | 4.7 | 58 |
| 290 | Durable Clinical Responses in Heavily Pretreated Patients with Relapsed/Refractory Multiple Myeloma: Updated Results from a Multicenter Study of bb2121 Anti-Bcma CAR T Cell Therapy. *Blood*, **2017**, 130, 740-740 | 2.2 | 58 |
| 289 | Sotatercept, a soluble activin receptor type 2A IgG-Fc fusion protein for the treatment of anemia and bone loss. *Current Opinion in Molecular Therapeutics*, **2010**, 12, 586-97 | | 58 |
| 288 | Initial Results from a Phase 1 Clinical Study of bb21217, a Next-Generation Anti Bcma CAR T Therapy. *Blood*, **2018**, 132, 488-488 | 2.2 | 55 |
| 287 | Thalidomide and immunomodulatory drugs as cancer therapy. *Current Opinion in Oncology*, **2002**, 14, 635-40 | 4.2 | 49 |
| 286 | Updated Results from an Ongoing Phase 1 Clinical Study of bb21217 Anti-Bcma CAR T Cell Therapy. *Blood*, **2019**, 134, 927-927 | 2.2 | 48 |
| 285 | The role of bisphosphonates in multiple myeloma: mechanisms, side effects, and the future. *Oncologist*, **2011**, 16, 651-62 | 5.7 | 47 |
| 284 | Pan-Cancer Efficacy of Vemurafenib in -Mutant Non-Melanoma Cancers. *Cancer Discovery*, **2020**, 10, 657-663 | 24.4 | 46 |
| 283 | p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications. *British Journal of Haematology*, **2008**, 141, 598-606 | 4.5 | 46 |
| 282 | Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma: A Nonrandomized Clinical Trial. *JAMA Oncology*, **2018**, 4, e183267 | 13.4 | 45 |

| | | | |
|---|---|---|---|
| 281 | bb2121 anti-BCMA CAR T-cell therapy in patients with relapsed/refractory multiple myeloma: Updated results from a multicenter phase I study.. *Journal of Clinical Oncology*, **2018**, 36, 8007-8007 | 2.2 | 45 |
| 280 | NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2016**, 14, 389-400 | 7.3 | 44 |
| 279 | Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations. *British Journal of Haematology*, **2015**, 169, 843-50 | 4.5 | 42 |
| 278 | Current developments in immunotherapy in the treatment of multiple myeloma. *Cancer*, **2018**, 124, 2075-2085 | 6.4 | 42 |
| 277 | Updated Results from the Phase I CRB-402 Study of Anti-Bcma CAR-T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma: Correlation of Expansion and Duration of Response with T Cell Phenotypes. *Blood*, **2020**, 136, 25-26 | 2.2 | 39 |
| 276 | The role of cement augmentation with percutaneous vertebroplasty and balloon kyphoplasty for the treatment of vertebral compression fractures in multiple myeloma: a consensus statement from the International Myeloma Working Group (IMWG). *Blood Cancer Journal*, **2019**, 9, 27 | 7 | 36 |
| 275 | Myeloma and Bone Disease. *Current Osteoporosis Reports*, **2017**, 15, 483-498 | 5.4 | 35 |
| 274 | Novel bone-targeted strategies in oncology. *Clinical Cancer Research*, **2010**, 16, 4084-93 | 12.9 | 35 |
| 273 | How to Train Your T Cells: Overcoming Immune Dysfunction in Multiple Myeloma. *Clinical Cancer Research*, **2020**, 26, 1541-1554 | 12.9 | 35 |
| 272 | Final Results of a Phase 2 Trial of Extended Treatment (tx) with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (KRd) Plus Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (NDMM). *Blood*, **2016**, 128, 675-675 | 2.2 | 34 |
| 271 | Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group. *Lancet Oncology, The*, **2021**, 22, e119-e130 | 21.7 | 33 |
| 270 | Panobinostat and Multiple Myeloma in 2018. *Oncologist*, **2018**, 23, 516-517 | 5.7 | 32 |
| 269 | Bone Marker-Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Results of the Z-MARK Study. *Clinical Cancer Research*, **2016**, 22, 1378-84 | 12.9 | 32 |
| 268 | Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. *Lancet Oncology, The*, **2021**, 22, e105-e118 | 21.7 | 32 |
| 267 | Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myeloma. *Leukemia*, **2021**, 35, 255-258 | 10.7 | 32 |
| 266 | Ixazomib for the treatment of multiple myeloma. *Expert Opinion on Pharmacotherapy*, **2018**, 19, 1949-1968 | 4 | 32 |
| 265 | First-in-human multicenter study of bb2121 anti-BCMA CAR T-cell therapy for relapsed/refractory multiple myeloma: Updated results.. *Journal of Clinical Oncology*, **2017**, 35, 3010-3010 | 2.2 | 31 |
| 264 | Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma. *British Journal of Haematology*, **2017**, 176, 783-795 | 4.5 | 30 |

| | | | |
|---|---|---|---|
| 263 | Biomarkers of bone remodeling in multiple myeloma patients to tailor bisphosphonate therapy. *Clinical Cancer Research*, **2014**, 20, 3955-61 | 12.9 | 27 |
| 262 | Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics from a Phase I Study of PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). *Blood*, **2019**, 134, 1869-1869 | 2.2 | 27 |
| 261 | A Phase Ib/II Study of Oprozomib in Patients with Advanced Multiple Myeloma and Waldenström Macroglobulinemia. *Clinical Cancer Research*, **2019**, 25, 4907-4916 | 12.9 | 25 |
| 260 | Successful anti-CD19 CAR T-cell therapy in HIV-infected patients with refractory high-grade B-cell lymphoma. *Cancer*, **2019**, 125, 3692-3698 | 6.4 | 25 |
| 259 | Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma. *Blood*, **2020**, 136, 2513-2523 | 2.2 | 25 |
| 258 | Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing. *Leukemia*, **2018**, 32, 1838-1841 | 10.7 | 24 |
| 257 | Role of the RANK/RANKL Pathway in Multiple Myeloma. *Clinical Cancer Research*, **2019**, 25, 12-20 | 12.9 | 24 |
| 256 | Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients. *Clinical Interventions in Aging*, **2012**, 7, 331-8 | 4 | 23 |
| 255 | Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma. *British Journal of Haematology*, **2018**, 182, 231-244 | 4.5 | 23 |
| 254 | Denosumab for the treatment of bone disease in solid tumors and multiple myeloma. *Future Oncology*, **2018**, 14, 195-203 | 3.6 | 22 |
| 253 | Delineating the mTOR kinase pathway using a dual TORC1/2 inhibitor, AZD8055, in multiple myeloma. *Molecular Cancer Therapeutics*, **2014**, 13, 2489-500 | 6.1 | 21 |
| 252 | Therapeutic use of immunomodulatory drugs in the treatment of multiple myeloma. *Expert Review of Anticancer Therapy*, **2006**, 6, 1239-47 | 3.5 | 21 |
| 251 | A Phase I, Open-Label Study to Evaluate the Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity of PF-06863135, a B-Cell Maturation Antigen/CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Advanced Multiple Myeloma. *Blood*, **2018**, 132, 3229-3229 | 2.2 | 21 |
| 250 | Lenalidomide, Bortezomib, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma: Encouraging Efficacy in High Risk Groups with Updated Results of a Phase I/II Study. *Blood*, **2008**, 112, 92-92 | 2.2 | 21 |
| 249 | Bone anabolic agents for the treatment of multiple myeloma. *Cancer Microenvironment*, **2011**, 4, 339-49 | 6.1 | 19 |
| 248 | Preliminary Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Subcutaneously (SC) Administered PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). *Blood*, **2020**, 136, 8-9 | 2.2 | 19 |
| 247 | Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy, in Patients with Relapsed and Refractory Multiple Myeloma: Updated Results from Phase 1 CRB-401 Study. *Blood*, **2020**, 136, 26-27 | 2.2 | 19 |
| 246 | Preliminary Results from a Phase Ib Study of Isatuximab in Combination with Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma. *Blood*, **2016**, 128, 2123-2123 | 2.2 | 19 |

| | | | |
|---|---|---|---|
| 245 | Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. *Lancet Oncology, The*, **2021**, 22, 1582-1596 | 21.7 | 19 |
| 244 | A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma. *Clinical Cancer Research*, **2019**, 25, 478-486 | 12.9 | 19 |
| 243 | Niche-Based Screening in Multiple Myeloma Identifies a Kinesin-5 Inhibitor with Improved Selectivity over Hematopoietic Progenitors. *Cell Reports*, **2015**, 10, 755-770 | 10.6 | 18 |
| 242 | Bone Disease in Multiple Myeloma. *Cancer Treatment and Research*, **2016**, 169, 251-270 | 3.5 | 18 |
| 241 | Advances in supportive care for multiple myeloma. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2014**, 12, 502-11 | 7.3 | 17 |
| 240 | Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, Combines Safely with Pomalidomide and Dexamethasone and Shows Promosing Early Results in Relapsed-and-Refractory Myeloma (ACE-MM-102 Study). *Blood*, **2015**, 126, 4228-4228 | 2.2 | 17 |
| 239 | Final Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study of Single-Agent Oprozomib in Patients with Hematologic Malignancies. *Blood*, **2016**, 128, 2110-2110 | 2.2 | 17 |
| 238 | VE-BASKET, a Simon 2-stage adaptive design, phase II, histology-independent study in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m): Activity of vemurafenib (VEM) with or without cetuximab (CTX) in colorectal cancer (CRC).. *Journal of Clinical Oncology*, **2014**, 32, 3518-3518 | 2.2 | 17 |
| 237 | Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma. *Clinical Cancer Research*, **2016**, 22, 5688-5695 | 12.9 | 17 |
| 236 | Role of decorin in multiple myeloma (MM) bone marrow microenvironment. *Journal of Bone and Mineral Research*, **2015**, 30, 465-70 | 6.3 | 15 |
| 235 | Efficacy of Vemurafenib in Patients With Non-Small-Cell Lung Cancer With V600 Mutation: An Open-Label, Single-Arm Cohort of the Histology-Independent VE-BASKET Study. *JCO Precision Oncology*, **2019**, 3, | 3.6 | 15 |
| 234 | ACY-241, a Novel, HDAC6 Selective Inhibitor: Synergy with Immunomodulatory (IMiD ) Drugs in Multiple Myeloma (MM) Cells and Early Clinical Results (ACE-MM-200 Study). *Blood*, **2015**, 126, 3040-3040 | 2.2 | 15 |
| 233 | Selective HDAC6 Inhibitor ACY-241, an Oral Tablet, Combined with Pomalidomide and Dexamethasone: Safety and Efficacy of Escalation and Expansion Cohorts in Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma (ACE-MM-200 Study). *Blood*, **2016**, 128, 3307-3307 | 2.2 | 15 |
| 232 | Myeloma bone disease: pathogenesis and treatment. *Clinical Advances in Hematology and Oncology*, **2017**, 15, 285-295 | 0.6 | 15 |
| 231 | A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America. *Journal of Medical Economics*, **2018**, 21, 525-536 | 2.4 | 14 |
| 230 | ACY-1215, a Selective Histone Deacetylase (HDAC) 6 Inhibitor: Interim Results Of Combination Therapy With Bortezomib In Patients With Multiple Myeloma (MM). *Blood*, **2013**, 122, 759-759 | 2.2 | 14 |
| 229 | Vemurafenib in Patients With Relapsed Refractory Multiple Myeloma Harboring Mutations: A Cohort of the Histology-Independent VE-BASKET Study. *JCO Precision Oncology*, **2018**, 2, | 3.6 | 14 |
| 228 | New monoclonal antibodies on the horizon in multiple myeloma. *Therapeutic Advances in Hematology*, **2017**, 8, 41-53 | 5.7 | 13 |

| | | | |
|---|---|---|---|
| 227 | Current Treatment Strategies for Multiple Myeloma. *JCO Oncology Practice*, **2020**, 16, 5-14 | 2.3 | 13 |
| 226 | BCL2 blockade overcomes MCL1 resistance in multiple myeloma. *Leukemia*, **2019**, 33, 2098-2102 | 10.7 | 13 |
| 225 | Phase II Trial of Lenalidomide, Bortezomib, and Dexamethasone In Patients (pts) with Relapsed and Relapsed/Refractory Multiple Myeloma (MM): Updated Efficacy and Safety Data After >2 Years of Follow-up. *Blood*, **2010**, 116, 3049-3049 | 2.2 | 12 |
| 224 | Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MM).. *Journal of Clinical Oncology*, **2021**, 39, 8006-8006 | 2.2 | 12 |
| 223 | Safety and efficacy of vorinostat, bortezomib, doxorubicin and dexamethasone in a phase I/II study for relapsed or refractory multiple myeloma (VERUMM study: vorinostat in elderly, relapsed and unfit multiple myeloma). *Haematologica*, **2018**, 103, e473-e479 | 6.6 | 11 |
| 222 | Multiple myeloma. *Current Treatment Options in Oncology*, **2000**, 1, 73-82 | 5.4 | 11 |
| 221 | Novel Three□and Four□Drug Combinations of Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide, for Newly Diagnosed Multiple Myeloma: Encouraging Results From the Multi-Center, Randomized, Phase 2 EVOLUTION Study.. *Blood*, **2009**, 114, 127-127 | 2.2 | 11 |
| 220 | Rocilinostat (ACY-1215), a Selective HDAC6 Inhibitor, Alone and in Combination with Bortezomib in Multiple Myeloma: Preliminary Results From the First-in-Humans Phase I/II Study. *Blood*, **2012**, 120, 4061-4061 | 2.2 | 11 |
| 219 | MM-005: A Phase 1 Trial Of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone (PVD) In Relapsed and/Or Refractory Multiple Myeloma (RRMM). *Blood*, **2013**, 122, 1969-1969 | 2.2 | 11 |
| 218 | Phase IB study of cabozantinib in patients with relapsed and/or refractory multiple myeloma. *Blood* , **2016**, 127, 2355-6 | 2.2 | 11 |
| 217 | Clinical Grade "SNaPshot" Genetic Mutation Profiling in Multiple Myeloma. *EBioMedicine*, **2015**, 2, 71-3 | 8.8 | 10 |
| 216 | Updated Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study of Single-Agent Oprozomib in Patients with Waldenstr□m Macroglobulinemia (WM). *Blood*, **2014**, 124, 1715-1715 | 2.2 | 10 |
| 215 | Phase 1B Results of Ricolinostat (ACY-1215) Combination Therapy with Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma (MM). *Blood*, **2014**, 124, 4764-4764 | 2.2 | 10 |
| 214 | Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, in Combination with Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma: Phase 1b Results (ACY-100 Study). *Blood*, **2015**, 126, 1827-1827 | 2.2 | 10 |
| 213 | A Phase 1, Multicenter Study of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone in Patients with Proteasome Inhibitor Exposed and Lenalidomide-Refractory Myeloma (Trial MM-005). *Blood*, **2015**, 126, 3036-3036 | 2.2 | 10 |
| 212 | Effect of the BET Inhibitor, Cpi-0610, Alone and in Combination with Lenalidomide in Multiple Myeloma. *Blood*, **2015**, 126, 4255-4255 | 2.2 | 10 |
| 211 | Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia. *Leukemia*, **2021**, | 10.7 | 10 |
| 210 | Consensus in the Management of Multiple Myeloma in India at Myeloma State of the Art 2016 Conference. *Indian Journal of Hematology and Blood Transfusion*, **2017**, 33, 15-21 | 0.7 | 9 |

| | | | |
|---|---|---|---|
| 209 | Once-weekly (70 mg/m ) vs twice-weekly (56 mg/m ) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION-1 trials. *Cancer Medicine*, **2020**, 9, 2989-2996 | 4.8 | 9 |
| 208 | Progression-Free Survival Analysis of Denosumab Vs Zoledronic Acid in Intent to Transplant Multiple Myeloma Patients Based on Treatment Regimen and Baseline Characteristics. *Blood*, **2019**, 134, 606-606 | 2.2 | 9 |
| 207 | A Phase I/II Open-Label Multicenter Study Of The Cyclin Kinase Inhibitor AT7519M Alone and In Combination With Bortezomib In Patients With Previously Treated Multiple Myeloma. *Blood*, **2013**, 122, 1976-1976 | 2.2 | 9 |
| 206 | Vemurafenib (VEM) in Relapsed Refractory Multiple Myeloma Harboring BRAFV600 Mutations (V600m): A Cohort of the Histology-Independent VE-Basket Study. *Blood*, **2015**, 126, 4263-4263 | 2.2 | 9 |
| 205 | Phase 2 Study of Carfilzomib (CFZ) with or without Filanesib (FIL) in Patients with Advanced Multiple Myeloma (MM). *Blood*, **2015**, 126, 728-728 | 2.2 | 9 |
| 204 | Efficacy of vemurafenib in patients (pts) with non-small cell lung cancer (NSCLC) with BRAFV600 mutation.. *Journal of Clinical Oncology*, **2017**, 35, 9074-9074 | 2.2 | 9 |
| 203 | Universal Updated Phase 1 Data Validates the Feasibility of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma. *Blood*, **2021**, 138, 651-651 | 2.2 | 9 |
| 202 | Updated Clinical and Correlative Results from the Phase I CRB-402 Study of the BCMA-Targeted CAR T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma. *Blood*, **2021**, 138, 548-548 | 2.2 | 9 |
| 201 | Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: A phase 1b study. *American Journal of Hematology*, **2019**, 94, 794-802 | 7.1 | 8 |
| 200 | Progression-Free Survival Subset Analysis - Denosumab Vs Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Double-Dummy, Randomized Controlled Phase 3 Study. *Blood*, **2018**, 132, 1969-1969 | 2.2 | 8 |
| 199 | Updated Results of a Phase 2 Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVd-lite) in Transplant-Ineligible Multiple Myeloma. *Blood*, **2019**, 134, 3178-3178 | 2.2 | 8 |
| 198 | Idecabtagene Vicleucel (ide-cel, bb2121) in Relapsed and Refractory Multiple Myeloma: Analyses of High-Risk Subgroups in the KarMMa Study. *Blood*, **2020**, 136, 37-38 | 2.2 | 8 |
| 197 | VE-BASKET, a first-in-kind, phase II, histology-independent basket study of vemurafenib (VEM) in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m).. *Journal of Clinical Oncology*, **2014**, 32, 2533-2533 | 2.2 | 8 |
| 196 | Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in relapsed and refractory multiple myeloma: Updated KarMMa results.. *Journal of Clinical Oncology*, **2021**, 39, 8016-8016 | 2.2 | 8 |
| 195 | Kaposi's sarcoma-associated herpesvirus gene sequences are detectable at low copy number in primary amyloidosis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2000**, 7, 126-32 | 2.7 | 7 |
| 194 | Efficacy and Safety of Idecabtagene Vicleucel (ide-cel, bb2121) in Elderly Patients with Relapsed and Refractory Multiple Myeloma: KarMMa Subgroup Analysis. *Blood*, **2020**, 136, 16-17 | 2.2 | 7 |
| 193 | ACY-1215, a Selective Histone Deacetylase (HDAC) 6 Inhibitor, In Combination With Lenalidomide and Dexamethasone (dex), Is Well Tolerated Without Dose Limiting Toxicity (DLT) In Patients (Pts) With Multiple Myeloma (MM) At Doses Demonstrating Biologic Activity: Interim Results Of a Phase 1b Trial. *Blood*, **2013**, 122, 3190-3190 | 2.2 | 7 |
| 192 | A Phase II Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVD lite) for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma. *Blood*, **2014**, 124, 3454-3454 | 2.2 | 7 |

| | | | |
|---|---|---|---|
| 191 | A Phase II Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVD-lite) for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma. *Blood*, **2015**, 126, 4217-4217 | 2.2 | 7 |
| 190 | Phase II MMRC trial of extended treatment with carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (DEX) plus autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (NDMM).. *Journal of Clinical Oncology*, **2015**, 33, 8510-8510 | 2.2 | 7 |
| 189 | Impact of denosumab (DMB) compared with zoledronic acid (ZA) on renal function in the treatment of myeloma bone disease.. *Journal of Clinical Oncology*, **2017**, 35, 8005-8005 | 2.2 | 7 |
| 188 | Denosumab compared with zoledronic acid on PFS in multiple myeloma: exploratory results of an international phase 3 study. *Blood Advances*, **2021**, 5, 725-736 | 7.8 | 7 |
| 187 | regulates the action of nitrogen-containing bisphosphonates on bone. *Science Translational Medicine*, **2020**, 12, | 17.5 | 6 |
| 186 | Identifying professional education gaps and barriers in multiple myeloma patient care: findings of the Managing Myeloma Continuing Educational Initiative Advisory Committee. *Clinical Lymphoma, Myeloma and Leukemia*, **2014**, 14, 356-69 | 2 | 6 |
| 185 | Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group.. *Lancet Haematology,the*, **2022**, 9, e143-e161 | 14.6 | 6 |
| 184 | Molecular and Phenotypic Profiling of Drug Product and Post-Infusion Samples from CRB-402, an Ongoing: Phase I Clinical Study of bb21217 a BCMA-Directed CAR T Cell Therapy. *Blood*, **2020**, 136, 3-4 | 2.2 | 6 |
| 183 | Lenalidomide, Bortezomib, and Dexamethasone (Rev/Vel/Dex) as Front-Line Therapy for Patients with Multiple Myeloma (MM): Preliminary Results of a Phase 1/2 Study.. *Blood*, **2007**, 110, 187-187 | 2.2 | 6 |
| 182 | Phase 1 Study of Tabalumab, a Human Anti-BAFF Antibody and Bortezomib in Patients with Previously-Treated Multiple Myeloma. *Blood*, **2012**, 120, 447-447 | 2.2 | 6 |
| 181 | Ricolinostat (ACY-1215), a Selective HDAC6 Inhibitor, in Combination with Lenalidomide and Dexamethasone: Results of a Phase 1b Trial in Relapsed and Relapsed Refractory Multiple Myeloma. *Blood*, **2014**, 124, 4772-4772 | 2.2 | 6 |
| 180 | A phase 1 multicenter study evaluating KITE-585, an autologous anti-BCMA CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma.. *Journal of Clinical Oncology*, **2018**, 36, TPS3103-TPS3103 | 2.2 | 6 |
| 179 | CC-92480, a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD) Agent, in Combination with Dexamethasone (DEX) and Bortezomib (BORT) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Phase 1/2 Study CC-92480-MM-002. *Blood*, **2021**, 138, 2731-2731 | 2.2 | 6 |
| 178 | Sequencing of nontransplant treatments in multiple myeloma patients with active disease. *Hematology American Society of Hematology Education Program*, **2016**, 2016, 495-503 | 3.1 | 6 |
| 177 | Current management and emerging treatment strategies for multiple myeloma. *Rinsho Ketsueki/the Japanese Journal of Clinical Hematology*, **2019**, 60, 1243-1256 | 1.8 | 5 |
| 176 | A Phase II Study of Elotuzumab in Combination with Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma. *Blood*, **2019**, 134, 3169-3169 | 2.2 | 5 |
| 175 | Targeting Bcl-2 as Therapy for Multiple Myeloma.. *Blood*, **2005**, 106, 109-109 | 2.2 | 5 |
| 174 | Lenalidomide, Bortezomib, and Dexamethasone (Rev/Vel/Dex) in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Results of a Phase II Study.. *Blood*, **2007**, 110, 2714-2714 | 2.2 | 5 |

| | | | |
|---|---|---|---|
| 173 | Lenalidomide, Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Updated Results of Phase I/II MMRC Trial.. *Blood*, **2009**, 114, 132-132 | 2.2 | 5 |
| 172 | Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, in Combonation with Lenalidomide and Dexamethasone in Patients with Relapsed and Relapsed-and-Refractory Multiple Myeloma: Phase 1b Results (ACE-MM-101 Study). *Blood*, **2015**, 126, 3055-3055 | 2.2 | 5 |
| 171 | Phase 1 Dose-Escalation Study of Sotatercept (ACE-011) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma. *Blood*, **2015**, 126, 4241-4241 | 2.2 | 5 |
| 170 | Early MRD negativity to predict deepening myeloma response in relapsed/refractory multiple myeloma (RRMM) patients treated with bb2121 anti-BCMA CAR T cells.. *Journal of Clinical Oncology* , **2018**, 36, 8024-8024 | 2.2 | 5 |
| 169 | How to Treat High-Risk Myeloma at Diagnosis and Relapse. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2021**, 41, 291-309 | 7.1 | 5 |
| 168 | Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma. *Leukemia*, **2021**, 35, 3526-3533 | 10.7 | 5 |
| 167 | Renal response in real-world carfilzomib- vs bortezomib-treated patients with relapsed or refractory multiple myeloma. *Blood Advances*, **2021**, 5, 367-376 | 7.8 | 5 |
| 166 | Treatment of Smoldering Multiple Myeloma: Ready for Prime Time?. *Cancers*, **2020**, 12, | 6.6 | 4 |
| 165 | Case records of the Massachusetts General Hospital: Case 29-2011: A 66-year-old woman with cardiac and renal failure. *New England Journal of Medicine*, **2011**, 365, 1129-38 | 59.2 | 4 |
| 164 | Arachidonic Acid Induces Ferroptosis-Mediated Cell-Death in Multiple Myeloma. *Blood*, **2018**, 132, 4498-4498 | 2.2 | 4 |
| 163 | AT7519, a Novel Small Molecule Multi-Cyclin Dependent Kinase Inhibitor, Induces Apoptosis in Multiple Myeloma VIA GSK3□*Blood*, **2008**, 112, 251-251 | 2.2 | 4 |
| 162 | Perifosine in Combination with Bortezomib and Dexamethasone Extends Progression-Free Survival and Overall Survival in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezombib: Updated Phase I/II Trial Results.. *Blood*, **2009**, 114, 1869-1869 | 2.2 | 4 |
| 161 | An Open-Label Phase I Study of the Safety and Efficacy of RAD001 in Combination with Lenalidomide in the Treatment of Patients with Relapsed and Relapsed/Refractory Multiple Myeloma.. *Blood*, **2009**, 114, 3856-3856 | 2.2 | 4 |
| 160 | B Cell Lymphoma In Association with Multiple Myeloma: Analysis of the Biologic Relationship. *Blood* , **2011**, 118, 1590-1590 | 2.2 | 4 |
| 159 | MM-005: Phase 1 trial of pomalidomide (POM), bortezomib (BORT), and low-dose dexamethasone (LoDEX [PVD]) in lenalidomide (LEN)-refractory and proteasome inhibitor (PI)-exposed myeloma.. *Journal of Clinical Oncology*, **2014**, 32, 8589-8589 | 2.2 | 4 |
| 158 | Psychosocial effects of the relaxation response resiliency program (SMART-3RP) in patients with MGUS and smoldering multiple myeloma: A waitlist controlled randomized clinical trial.. *Journal of Clinical Oncology*, **2017**, 35, 10051-10051 | 2.2 | 4 |
| 157 | A phase II study of elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma.. *Journal of Clinical Oncology*, **2018**, 36, 8012-8012 | 2.2 | 4 |
| 156 | Final results of a phase Ib study of isatuximab (ISA) plus pomalidomide (Pom) and dexamethasone (dex) in relapsed/refractory multiple myeloma (RRMM).. *Journal of Clinical Oncology*, **2018**, 36, 8038-8038 | 2.2 | 4 |

| | | | |
|---|---|---|---|
| 155 | Response to Comment-Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published in Lancet Oncology. *Dentistry Journal*, **2019**, 7, | 3.1 | 3 |
| 154 | Markers of Initial and Long-Term Responses to Idecabtagene Vicleucel (Ide-Cel; bb2121) in the CRB-401 Study in Relapsed/Refractory Multiple Myeloma. *Blood*, **2019**, 134, 4328-4328 | 2.2 | 3 |
| 153 | Phase 1 Study of CART-Ddbcma, a CAR-T Therapy Utilizing a Novel Synthetic Binding Domain for the Treatment of Subjects with Relapsed and Refractory Multiple Myeloma. *Blood*, **2020**, 136, 2-2 | 2.2 | 3 |
| 152 | Promoting Osteoblastogenesis Using a Novel Dkk-1 Neutralizing Antibody in the Treatment of Multiple Myeloma Related Bone Disease. *Blood*, **2008**, 112, 2739-2739 | 2.2 | 3 |
| 151 | Updated Results of a Phase I Study of RAD001 In Combination with Lenalidomide In Patients with Relapsed or Refractory Multiple Myeloma with Pharmacodynamic and Pharmacokinetic Analysis. *Blood*, **2010**, 116, 3051-3051 | 2.2 | 3 |
| 150 | Initial Results of a Phase 1/2a, Dose Escalation Study of PVX-410 Multi-Peptide Cancer Vaccine in Patients with Smoldering Multiple Myeloma (SMM). *Blood*, **2014**, 124, 4737-4737 | 2.2 | 3 |
| 149 | Vemurafenib in Patients with Erdheim-Chester Disease (ECD) and Langerhans Cell Histiocytosis (LCH) Harboring BRAFV600 Mutations: A Cohort of the Histology-Independent VE-Basket Study. *Blood*, **2016**, 128, 480-480 | 2.2 | 3 |
| 148 | Impact of age on efficacy and safety of daratumumab in combination with lenalidomide and dexamethasone (D-Rd) in patients (pts) with transplant-ineligible newly diagnosed multiple myeloma (NDMM): MAIA.. *Journal of Clinical Oncology*, **2019**, 37, 8035-8035 | 2.2 | 3 |
| 147 | The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Potent and Selective Cytotoxicity against CD138 Positive Multiple Myeloma Cells in Vitro and in Vivo.. *Blood*, **2008**, 112, 1716-1716 | 2.2 | 3 |
| 146 | Single-Cell Profiling Reveals Metabolic Reprogramming as a Resistance Mechanism in -Mutated Multiple Myeloma. *Clinical Cancer Research*, **2021**, 27, 6432-6444 | 12.9 | 3 |
| 145 | How We Approach Smoldering Multiple Myeloma. *Journal of Clinical Oncology*, **2020**, 38, 1119-1125 | 2.2 | 2 |
| 144 | The monoclonal antibody nBT062 conjugated to maytansinoids has potent and selective cytotoxicity against CD138 positive multiple myeloma cells in vitro and in vivo. *Nature Precedings*, **2008**, | | 2 |
| 143 | Minimal residual disease in multiple myeloma: why, when, where. *Hematology American Society of Hematology Education Program*, **2021**, 2021, 37-45 | 3.1 | 2 |
| 142 | Analysis of Hospitalization and Readmissions after CAR T Cell Therapy. *Blood*, **2018**, 132, 2301-2301 | 2.2 | 2 |
| 141 | Patient Preferences for Multiple Myeloma (MM) Treatment: Interim Analysis of a Discrete Choice Experiment. *Blood*, **2018**, 132, 3586-3586 | 2.2 | 2 |
| 140 | Mature Osteoblasts Provide a Protective Niche Against Multiple Myeloma Growth and Survival within the Tumor Microenvironment. *Blood*, **2018**, 132, 4476-4476 | 2.2 | 2 |
| 139 | Lenalidomide and Bortezomib Inhibit Osteoclast Differentiation and Activation in Multiple Myeloma: Clinical Implications.. *Blood*, **2006**, 108, 3485-3485 | 2.2 | 2 |
| 138 | High Response Rates and Encouraging Time-to-Event Data with Lenalidomide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Final Results of a Phase I/II Study.. *Blood*, **2009**, 114, 1218-1218 | 2.2 | 2 |

| | | | |
|---|---|---|---|
| 137 | Bone Marker-Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Final Results of the Z-MARK Study. *Blood*, **2012**, 120, 4077-4077 | 2.2 | 2 |
| 136 | Updated Results of a Phase 1/2a, Dose Escalation Study of Pvx-410 Multi-Peptide Cancer Vaccine in Patients with Smoldering Multiple Myeloma (SMM). *Blood*, **2015**, 126, 4246-4246 | 2.2 | 2 |
| 135 | Final Results of a Phase 1/2a, Dose Escalation Study of Pvx-410 Multi-Peptide Cancer Vaccine in Patients with Smoldering Multiple Myeloma (SMM). *Blood*, **2016**, 128, 2124-2124 | 2.2 | 2 |
| 134 | MM-005: A phase I trial of pomalidomide, bortezomib, and low-dose dexamethasone (PVD) in relapsed and/or refractory multiple myeloma (RRMM).. *Journal of Clinical Oncology*, **2013**, 31, 8584-8584 | 2.2 | 2 |
| 133 | Multiple myeloma cells induce lipolysis in adipocytes and uptake fatty acids through fatty acid transporter proteins. *Blood*, **2021**, | 2.2 | 2 |
| 132 | Lifestyle considerations in multiple myeloma. *Blood Cancer Journal*, **2021**, 11, 172 | 7 | 2 |
| 131 | Perspectives in the Rapidly Evolving Treatment Landscape of Multiple Myeloma: Expert Review of New Data Presentations from ASH 2019. *Clinical Lymphoma, Myeloma and Leukemia*, **2020**, 20, 724-735 | 2 | 2 |
| 130 | Phase 1 Study of CART-ddBCMA, a CAR-T therapy utilizing a novel synthetic binding domain, for the treatment of subjects with relapsed and refractory multiple myeloma.. *Journal of Clinical Oncology*, **2021**, 39, 8015-8015 | 2.2 | 2 |
| 129 | Characteristics of neurotoxicity associated with idecabtagene vicleucel (ide-cel, bb2121) in patients with relapsed and refractory multiple myeloma (RRMM) in the pivotal phase II KarMMa study.. *Journal of Clinical Oncology*, **2021**, 39, 8036-8036 | 2.2 | 2 |
| 128 | A phase 1b study of once-weekly carfilzomib combined with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma. *American Journal of Hematology*, **2021**, 96, 226-233 | 7.1 | 2 |
| 127 | Low NCOR2 levels in multiple myeloma patients drive multidrug resistance via MYC upregulation. *Blood Cancer Journal*, **2021**, 11, 194 | 7 | 2 |
| 126 | The Pleiotropic Immunosuppressive Role of Osteoclasts in Multiple Myeloma. *Blood*, **2018**, 132, 4447-4447 | 12 | 1 |
| 125 | Requirement of Caspase-8 Versus Caspase-9 during Apoptosis in Multiple Myeloma Cells Induced by Bortezomib- or a Novel Proteasome Inhibitor NPI-0052.. *Blood*, **2005**, 106, 3378-3378 | 2.2 | 1 |
| 124 | The Role of B Cell-Activating Factor (BAFF) in the Biology of Multiple Myeloma (MM).. *Blood*, **2005**, 106, 3380-3380 | 2.2 | 1 |
| 123 | Treatment Patterns among Patients with Recently-Diagnosed Multiple Myeloma in a National Registry. *Blood*, **2008**, 112, 2374-2374 | 2.2 | 1 |
| 122 | Molecular Profiling of Extramedullary and Medullary Plasmacytomas.. *Blood*, **2009**, 114, 1806-1806 | 2.2 | 1 |
| 121 | Lenalidomide, Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone In Newly Diagnosed Multiple Myeloma (MM): Final Results of Phase I/II MMRC Trial. *Blood*, **2010**, 116, 1937-1937 | 2.2 | 1 |
| 120 | Bone Marker Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications In Patients with Multiple Myeloma: Interim Analysis Results of the Z-MARK Study. *Blood*, **2010**, 116, 2971-2971 | 2.2 | 1 |

| | | | |
|---|---|---|---|
| 119 | Selective Inhibition of HDAC6 with a New Prototype Inhibitor (ACY-1215) Overcomes Bortezomib Resistance In Multiple Myeloma (MM). *Blood*, **2010**, 116, 2997-2997 | 2.2 | 1 |
| 118 | CYC065, a Potent Derivative of Seliciclib Is Active In Multiple Myeloma In Preclinical Studies. *Blood*, **2010**, 116, 2999-2999 | 2.2 | 1 |
| 117 | Lenalidomide In Combination with the Activin Receptor Type II Murine Fc Protein RAP-011: Preclinical Rationale for a Novel Anti-Myeloma Strategy. *Blood*, **2010**, 116, 4075-4075 | 2.2 | 1 |
| 116 | Increased Sclerostin Secretion in Multiple Myeloma Results in Stimulation of Osteoclastogenesis and Inhibition of Osteoblastogenesis. *Blood*, **2011**, 118, 1819-1819 | 2.2 | 1 |
| 115 | Pharmacodynamic and Pharmacokinetic Properties of a Novel and Selective HDAC6 Inhibitor, ACY-1215, in Combination with Bortezomib in Multiple Myeloma. *Blood*, **2011**, 118, 2912-2912 | 2.2 | 1 |
| 114 | Biomarker Correlation with Outcomes in Patients with Relapsed or Refractory Multiple Myeloma on a Phase I Study of Everolimus in Combination with Lenalidomide,. *Blood*, **2011**, 118, 3966-3966 | 2.2 | 1 |
| 113 | Role of Selective HDAC6 Inhibition On Multiple Myeloma Bone Disease. *Blood*, **2012**, 120, 328-328 | 2.2 | 1 |
| 112 | Niche-Based Screening Identifies Novel Small Molecules That Overcome Stromal Effects in Multiple Myeloma. *Blood*, **2012**, 120, 571-571 | 2.2 | 1 |
| 111 | Final Results of a Phase 1/2 Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of Evofosfamide, a Hypoxia-Activated Prodrug, and Dexamethasone with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma. *Blood*, **2016**, 128, 2122-2122 | 2.2 | 1 |
| 110 | Concomitant Suppression of IKZF1, IRF4 and MYC Contribute to the Anti-Tumor Activity of the BET Inhibitor, Cpi-0610, in Disease Models of Multiple Myeloma. *Blood*, **2016**, 128, 3320-3320 | 2.2 | 1 |
| 109 | New Clinical and Research Directions in Myeloma-Related Bone Disease **2015**, 12, | | 1 |
| 108 | Evaluating results from the multiple myeloma subset of patients treated with denosumab or zoledronic acid (ZA) in a randomized phase III study.. *Journal of Clinical Oncology*, **2013**, 31, 8589-8589 | 2.2 | 1 |
| 107 | Preliminary safety and efficacy of TH-302, an investigational hypoxia-targeted drug, and dexamethasone (dex) in patients (pts) with relapsed/refractory multiple myeloma (RR MM).. *Journal of Clinical Oncology*, **2014**, 32, 8534-8534 | 2.2 | 1 |
| 106 | A multicenter, randomized, open-label, phase 2 study of carfilzomib with or without ARRY-520 (filanesib) in patients with advanced multiple myeloma.. *Journal of Clinical Oncology*, **2015**, 33, 8612-8612 | 2.2 | 1 |
| 105 | Vemurafenib in patients with BRAFV600 mutant glioma: A cohort of the histology-independent VE-basket study.. *Journal of Clinical Oncology*, **2017**, 35, 2004-2004 | 2.2 | 1 |
| 104 | Weekly carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed or refractory multiple myeloma (RRMM): A phase 1b study.. *Journal of Clinical Oncology*, **2018**, 36, 8022-8022 | 2.2 | 1 |
| 103 | Digital Health for Patients With Multiple Myeloma: An Unmet Need. *JCO Clinical Cancer Informatics*, **2021**, 5, 1096-1105 | 5.2 | 1 |
| 102 | Infectious Complications in Patients Treated with Idecabtagene Vicleucel for Relapsed and Refractory Multiple Myeloma. *Blood*, **2021**, 138, 3839-3839 | 2.2 | 1 |

| | | | |
|---|---|---|---|
| 101 | Quality of Life, Psychological Distress, and Prognostic Awareness in Caregivers of Patients with Multiple Myeloma. *Blood*, **2021**, 138, 3044-3044 | 2.2 | 1 |
| 100 | Dynamic transcriptional reprogramming leads to immunotherapeutic vulnerabilities in myeloma. *Nature Cell Biology*, **2021**, 23, 1199-1211 | 23.4 | 1 |
| 99 | Low Levels of Circulating CS1, a Newly Identified Multiple Myeloma (MM) Antigen for a Novel Humanized HuLuc63 Monoclonal Antibody, Is Detected in MM Patient Sera and Correlates with Active Disease.. *Blood*, **2007**, 110, 1509-1509 | 2.2 | 1 |
| 98 | Mature Osteoblasts Promote Multiple Myeloma Survival through Cell-Cell Contact and Immune Modulation Mechanisms. *Blood*, **2019**, 134, 1802-1802 | 2.2 | 1 |
| 97 | Polyunsaturated Fatty Acid (PUFA) Signaling Induces Ferroptosis-Mediated Cell-Death in Multiple Myeloma. *Blood*, **2019**, 134, 3108-3108 | 2.2 | 1 |
| 96 | Targeting Immune Suppressive Microenvironment By Immune Checkpoint Blockade in Multiple Myeloma. *Blood*, **2014**, 124, 27-27 | 2.2 | 1 |
| 95 | Preliminary safety and efficacy of evofosfamide (TH-302), an investigational hypoxia-activated prodrug, combined with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma (RR MM).. *Journal of Clinical Oncology*, **2015**, 33, 8579-8579 | 2.2 | 1 |
| 94 | Early Mortality in Newly Diagnosed Multiple Myeloma in the Context of Novel Drugs. *Blood*, **2015**, 126, 3315-3315 | 2.2 | 1 |
| 93 | Disruption of DEPTOR/mTORC1/mTORC2 Signaling Cascade Using a Novel Selective mTOR Kinase Inhibitor AZD8055 Results In Growth Arrest and Apoptosis In Multiple Myeloma Cells. *Blood*, **2010**, 116, 791-791 | 2.2 | 1 |
| 92 | Selective HDAC6 Inhibition Via ACY-1215, Either Alone or in Combination with Bortezomib, Restores Osteoblast Function and Suppresses Osteoclast Differentiation in Multiple Myeloma. *Blood*, **2011**, 118, 2908-2908 | 2.2 | 1 |
| 91 | Increased Sclerostin Secretion in Multiple Myeloma Plays a Central Role in Osteolytic Bone Disease. *Blood*, **2012**, 120, 3989-3989 | 2.2 | 1 |
| 90 | TEMPI: A Reversible Syndrome Following Treatment with Bortezomib. *Blood*, **2012**, 120, 986-986 | 2.2 | 1 |
| 89 | A Novel Bruton?s Tyrosine Kinase Inhibitor CC-292 In Combination With The Proteasome Inhibitor Carfilzomib Iimpacts Multiple Myeloma Bone Microenviroment With Resultant Anti-Myeloma Activity. *Blood*, **2013**, 122, 682-682 | 2.2 | 1 |
| 88 | Phase 1 Study Of TH-302, An Investigational Hypoxia-Targeted Drug, and Dexamethasone In Patients With Relapsed/Refractory Multiple Myeloma. *Blood*, **2013**, 122, 1948-1948 | 2.2 | 1 |
| 87 | Pilot Trial of the My Hematology Oncology Patient Experience (MyHOPE) for Multiple Myeloma (MM) Digital Solution in Patients with MM. *Blood*, **2020**, 136, 3-4 | 2.2 | 0 |
| 86 | Long-term safety and efficacy of pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in relapsed and refractory multiple myeloma (RRMM) patients enrolled in the MM-002 phase II trial.. *Journal of Clinical Oncology*, **2013**, 31, 8588-8588 | 2.2 | 0 |
| 85 | COVID-19 Vaccine Responsiveness in Patients with Multiple Myeloma and Waldenström Macroglobulinemia. *Blood*, **2021**, 138, 3801-3801 | 2.2 | 0 |
| 84 | Real-World Observations and Practical Considerations of Subcutaneous Daratumumab Administration in Multiple Myeloma. *Blood*, **2021**, 138, 5018-5018 | 2.2 | 0 |

| | | | |
|---|---|---|---|
| 83 | KarMMa-7, a Phase 1/2, Dose-Finding and Dose-Expansion Study of Combination Therapies with Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM). *Blood*, **2021**, 138, 4830-4830 | 2.2 | 0 |
| 82 | Efficacy of Daratumumab, Lenalidomide, and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma and Impaired Renal Function from the Phase 3 Maia Study Based on Lenalidomide Starting Dose. *Blood*, **2021**, 138, 1646-1646 | 2.2 | 0 |
| 81 | A Phase II Study of Lenalidomide, Ixazomib, Dexamethasone, and Daratumumab in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (AFT-41). *Blood*, **2021**, 138, 4776-4776 | 2.2 | 0 |
| 80 | Giving voice to patients: Understanding treatment preferences of patients with multiple myeloma (MM).. *Journal of Clinical Oncology*, **2019**, 37, e18302-e18302 | 2.2 | 0 |
| 79 | Outcomes of Patients with t(11;14) Multiple Myeloma: An International Myeloma Working Group Multicenter Study. *Blood*, **2019**, 134, 3066-3066 | 2.2 | 0 |
| 78 | Osteoclast-Induced Immunosuppression Occurs through Dysregulation of Immune Checkpoint Axes in Multiple Myeloma. *Blood*, **2019**, 134, 4382-4382 | 2.2 | 0 |
| 77 | Inhibition Of Myeloid Derived Suppressor Cells (MDSC) In The Multiple Myeloma Bone Marrow Microenvironment. *Blood*, **2013**, 122, 3089-3089 | 2.2 | 0 |
| 76 | Real-world evidence for carfilzomib dosing intensity on overall survival and treatment progression in multiple myeloma patients. *Journal of Oncology Pharmacy Practice*, **2021**, 10781552211015283 | 1.7 | 0 |
| 75 | Updates and rationale of clinical trials in multiple myeloma. *Advances in Cell and Gene Therapy*, **2019** , 2, e59 | 1.2 | |
| 74 | Pomalidomide for the treatment of relapsed and refractory multiple myeloma. *Expert Opinion on Orphan Drugs*, **2014**, 2, 1089-1108 | 1.1 | |
| 73 | A Novel in-Vivo Model to Examine Homing of Multiple Myeloma Cells in Postnatal, Inducible, and Reversible Loss of Mature Osteoblasts. *Blood*, **2020**, 136, 50-50 | 2.2 | |
| 72 | Comparison of Denosumab Versus Intravenous (IV) Bisphosphonate Use for Hypercalcemia in Multiple Myeloma. *Blood*, **2020**, 136, 14-16 | 2.2 | |
| 71 | Extending Dosing Intervals of Denosumab As a Maintenance Strategy in Multiple Myeloma: A Real-World Experience at a Large Academic Cancer Center. *Blood*, **2020**, 136, 13-13 | 2.2 | |
| 70 | Multiple Myeloma Cells Induce Lipolysis in Adipocytes and Uptake Fatty Acids through Fatty Acid Transporter Proteins. *Blood*, **2020**, 136, 41-42 | 2.2 | |
| 69 | NCOR2 Mutations Are Associated with IMiD Resistance in Human Myeloma Cells. *Blood*, **2020**, 136, 4-4 | 2.2 | |
| 68 | A phase 1, multicenter study evaluating the safety and efficacy of KITE-585, an autologous anti-BCMA CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma. *American Journal of Cancer Research*, **2021**, 11, 3285-3293 | 4.4 | |
| 67 | Quality of Life, Psychological Distress, and Prognostic Awareness in Patients with Multiple Myeloma. *Blood*, **2021**, 138, 4082-4082 | 2.2 | |
| 66 | Sustained Improvement in Health-Related Quality of Life in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone: Update of the Phase 3 MAIA Trial. *Blood*, **2021**, 138, 1655-1655 | 2.2 | |

| | | |
|---|---|---|
| 65 | Bone Marrow Adipocytes Induce Metabolic Reprogramming of Multiple Myeloma Cells. *Blood*, **2021**, 138, 1614-1614 | 2.2 |
| 64 | Mature Osteoblasts Are Critical Bone Marrow Niche Cells Regulating Multiple Myeloma Cell Growth, at Least in Part, By Affecting the Local Immune Microenvironment. *Blood*, **2021**, 138, 74-74 | 2.2 |
| 63 | Real-World Effectiveness of Bortezomib Plus Dexamethasone in Patients with t(11;14) Positive Multiple Myeloma. *Blood*, **2021**, 138, 4725-4725 | 2.2 |
| 62 | Meaningful Changes in Patient-Reported Outcomes in Relation to Best Clinical Response and Disease Progression: Post Hoc Analyses from MAIA. *Blood*, **2021**, 138, 4095-4095 | 2.2 |
| 61 | A Phase II Study of Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma. *Blood*, **2021**, 138, 5043-5043 | 2.2 |
| 60 | SDX-101 Is Cytotoxic and Overcomes Drug Resistance in Multiple Myeloma.. *Blood*, **2004**, 104, 3466-3466 | 2.2 |
| 59 | Bortezomib Targets Multiple Myeloma Endothelial Cells.. *Blood*, **2004**, 104, 4903-4903 | 2.2 |
| 58 | Targeting Mitochondrial Factor Smac/DIABLO as Therapy for Multiple Myeloma (MM).. *Blood*, **2004**, 104, 764-764 | 2.2 |
| 57 | Role of BAFF in Adhesion and Growth of Human Multiple Myeloma Cells in the Bone Marrow Microenvironment.. *Blood*, **2005**, 106, 627-627 | 2.2 |
| 56 | Upregulation of c-Jun Induces Cell Death Via Caspase-Triggered c-Abl Cleavage in Human Multiple Myeloma.. *Blood*, **2006**, 108, 3415-3415 | 2.2 |
| 55 | Bcl-2, Mcl-1 and p53 Expression Confer Sensitivity to Bcl-2 Inhibitor ABT-737 in Multiple Myeloma.. *Blood*, **2006**, 108, 3474-3474 | 2.2 |
| 54 | Attitudes toward Participation in Research, New Treatments, and Medication Side Effects among Multiple Myeloma and Myelodysplastic Syndrome Patients - The Patient Registries at Slone: Myeloma & MDS.. *Blood*, **2007**, 110, 3325-3325 | 2.2 |
| 53 | Multiple Myeloma Cell-Osteoblast Interaction Results in Impaired Bone Formation.. *Blood*, **2007**, 110, 4764-4764 | 2.2 |
| 52 | Association of high baseline ferritin with tocilizumab administration for CRS in relapsed/refractory multiple myeloma patients treated with bb2121 anti-BCMA CAR T cells.. *Journal of Clinical Oncology*, **2018**, 36, e15062-e15062 | 2.2 |
| 51 | Evolving Areas of Consensus and Disagreement Among Experts in Treatment of Patients with Multiple Myeloma (MM). *Blood*, **2018**, 132, 5664-5664 | 2.2 |
| 50 | Renal Response in Carfilzomib (K)- Versus Bortezomib (V)-Treated Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM) in the Real-World Practice Setting. *Blood*, **2018**, 132, 3253-3253 | 2.2 |
| 49 | Overcoming MCL1 Resistance in Multiple Myeloma. *Blood*, **2018**, 132, 472-472 | 2.2 |
| 48 | Once-weekly (70 mg/m2) versus twice-weekly (56 mg/m2) dosing of carfilzomib (CFZ) for patients (pts) with relapsed and/or refractory multiple myeloma (RRMM).. *Journal of Clinical Oncology*, **2019**, 37, e19505-e19505 | 2.2 |

| | | |
|---|---|---|
| 47 | Circulating Tumor DNA in the Peripheral Blood As Early Predictor of Clinical Outcome in Relapsed/ Refractory Multiple Myeloma. *Blood*, **2019**, 134, 4350-4350 | 2.2 |
| 46 | Determining Resistance Mechanisms in BRAF-mutated Multiple Myeloma. *Blood*, **2019**, 134, 316-316 | 2.2 |
| 45 | Defining the Differentiation States of Multiple Myeloma at Single Cell Resolution Reveals Opportunities for Immunotherapy. *Blood*, **2019**, 134, 3091-3091 | 2.2 |
| 44 | A phase II, single-arm study of denosumab in multiple myeloma patients with renal insufficiency.. *Journal of Clinical Oncology*, **2020**, 38, 8520-8520 | 2.2 |
| 43 | Clinical grade ?SNaPshot? genetic mutation profiling in multiple myeloma.. *Journal of Clinical Oncology*, **2014**, 32, e19571-e19571 | 2.2 |
| 42 | A randomized, double-blind, multinational trial comparing denosumab with zoledronic acid for treatment of bone disease in adults with newly diagnosed multiple myeloma.. *Journal of Clinical Oncology*, **2014**, 32, TPS8628-TPS8628 | 2.2 |
| 41 | Continuous lenalidomide (LEN) therapy versus observation following nonimmunomodulatory compound-based induction therapy in newly diagnosed multiple myeloma (NDMM): MM-027 trial.. *Journal of Clinical Oncology*, **2014**, 32, TPS8630-TPS8630 | 2.2 |
| 40 | Effect of the Pan-PIM Kinase Inhibitor, AZD1208, Alone and in Combination with Bortezomib in Multiple Myeloma. *Blood*, **2014**, 124, 5726-5726 | 2.2 |
| 39 | A Phase 1/2 Trial of TH-302 and Dexamethasone without or with Bortezomib (TBorD) in Patients with Relapsed/Refractory Multiple Myeloma. *Blood*, **2014**, 124, 2142-2142 | 2.2 |
| 38 | Denosumab compared with zoledronic acid for the treatment of bone disease in adults with newly diagnosed multiple myeloma: An international, randomized, double-blind trial.. *Journal of Clinical Oncology*, **2015**, 33, TPS8611-TPS8611 | 2.2 |
| 37 | Novel In Vivo Model of Multiple Myeloma Bone Disease Using Tricalcium Phosphate Artificial Bone Grafts. *Blood*, **2015**, 126, 4200-4200 | 2.2 |
| 36 | The KDM3A-KLF2-IRF4 Axis Maintains Myeloma Cell Survival. *Blood*, **2015**, 126, 3633-3633 | 2.2 |
| 35 | The Biologic Relevance of PIM Kinases in the Context of Multiple Myeloma and Their Potential As Therapeutic Targets in Combination Drug Therapy. *Blood*, **2015**, 126, 2992-2992 | 2.2 |
| 34 | the Use of Tailored Feedback to Improve Hematologist Competence and Clinical Decision Making for the Treatment of Patients with Multiple Myeloma: a Novel Web-Based Educational Solution. *Blood*, **2016**, 128, 3570-3570 | 2.2 |
| 33 | Comprehensive Genetic Interrogation of Circulating Multiple Myeloma Cells at Single Cell Resolution. *Blood*, **2016**, 128, 800-800 | 2.2 |
| 32 | Effect of the Wnt-Signaling Inhibitor Sclerostin and Bone Marrow Adipocytes on Multiple Myeloma. *Blood*, **2016**, 128, 2077-2077 | 2.2 |
| 31 | Identification and Validation of HLA-A24 XBP1us, XBP1sp, CD138, and CS1 Peptides to Generate Antigens Specific-Cytotoxic T Lymphocytes: Preclinical Basis for Vaccine Therapy in HLA-A24 Patients with Multiple Myeloma and Other Cancers. *Blood*, **2016**, 128, 5689-5689 | 2.2 |
| 30 | Interactions of the Mdm2/p53 and Proteasome Pathways: Implications for Combination Strategies to Enhance the Anti-Myeloma Activity of Bortezomib. *Blood*, **2008**, 112, 2651-2651 | 2.2 |

| | | |
|---|---|---|
| 29 | Sulforaphane and PEITC Augment Activity of Conventional and Novel Anti-Myeloma Drugs. *Blood*, **2008**, 112, 2648-2648 | 2.2 |
| 28 | Molecular Profiling of Extramedullary and Medullary Plasmacytomas. *Blood*, **2008**, 112, 5111-5111 | 2.2 |
| 27 | Dietary Supplement Vitamin C Significantly Abrogates Bortezomib-Induced Multiple Myeloma (MM) Cell Growth Inhibition. *Blood*, **2008**, 112, 3687-3687 | 2.2 |
| 26 | NPI-2358, a Novel Vascular Disrupting Agent Blocks Growth and Angiogenesis in Multiple Myeloma Cells.. *Blood*, **2009**, 114, 3842-3842 | 2.2 |
| 25 | Molecular Sequaele of Activin A-Dependent Osteoblast Inhibition in Myeloma.. *Blood*, **2009**, 114, 1789-1789 | 2.2 |
| 24 | CCL3 Impairs Osteoblast Function Via Downregulation of Osteocalcin.. *Blood*, **2009**, 114, 739-739 | 2.2 |
| 23 | AT9283, a Small Molecule Multi-Targeted Kinase Inhibitor Induces Antimyeloma Activity Via Potent Aurora Kinase and STAT3 Inhibition.. *Blood*, **2009**, 114, 3833-3833 | 2.2 |
| 22 | Overcoming p53 Loss with a Multi-Targeted Small Molecule Inhibitor in Multiple Myeloma.. *Blood*, **2009**, 114, 4915-4915 | 2.2 |
| 21 | Use of Alkylating Agents Among Patients with Multiple Myeloma in a National Registry, 2006-2008.. *Blood*, **2009**, 114, 4941-4941 | 2.2 |
| 20 | Bcl6 as a Novel Therapeutic Target in Multiple Myeloma (MM).. *Blood*, **2009**, 114, 295-295 | 2.2 |
| 19 | Comparison of Skeletal Complications and Treatment Patterns Associated with Early Versus Delayed Zoledronic Acid Therapy In Multiple Myeloma. *Blood*, **2010**, 116, 1956-1956 | 2.2 |
| 18 | AT9283, a Small Molecule Multi-Targeted Kinase Inhibitor with Potent Activity Against Aurora Kinase and STAT3 In Combination with Lenalidomide Results In Synergistic Anti-Myeloma Activity. *Blood*, **2010**, 116, 2994-2994 | 2.2 |
| 17 | Inhibition of Histone Deacetylase 6 Effects on Interaction of Tumor and Immune Cells In Multiple Myeloma. *Blood*, **2010**, 116, 2996-2996 | 2.2 |
| 16 | Molecular Profiling of Extramedullary and Medullary Plasmacytomas Compared to Multiple Myeloma. *Blood*, **2010**, 116, 4042-4042 | 2.2 |
| 15 | Targeting Bruton's Tyrosine Kinase As a Novel Approach to Inhibit Osteoclast Function in Multiple Myeloma. *Blood*, **2011**, 118, 2882-2882 | 2.2 |
| 14 | Perifosine Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezomib: Final Results of a Phase I/II Trial. *Blood*, **2011**, 118, 815-815 | 2.2 |
| 13 | Bone Marker Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Primary Analysis Results of the Z-MARK Study. *Blood*, **2011**, 118, 5122-5122 | 2.2 |
| 12 | The TEMPI Syndrome: Telangiectasias, Elevated Erythropoietin and Erythrocytosis, Monoclonal Gammopathy, Perinephric Fluid Collections, and Intrapulmonary Shunting. *Blood*, **2011**, 118, 1037-1037 | 2.2 |

| | | |
|---|---|---|
| 11 | The Multiple Myeloma Research Consortium (MMRC): Accelerated Start up and Accrual Metrics Speeds Drug Development. *Blood*, **2011**, 118, 1024-1024 | 2.2 |
| 10 | Immunomodulatory Effects of Histone Deacetylase 6 Inhibition in Suppressor Immune Cells in Multiple Myeloma. *Blood*, **2011**, 118, 128-128 | 2.2 |
| 9 | Myeloid Derived Suppressor Cells (MDSCs) Regulate Tumor Growth, Immune Response and Regulatory T Cell (Treg) Development in the Multiple Myeloma Bone Marrow Microenvironment. *Blood*, **2012**, 120, 565-565 | 2.2 |
| 8 | Mutational Profiling of Multiple Myeloma Bone Marrow Aspirates As a Clinical Tool for Personalized Treatment of Myeloma. *Blood*, **2012**, 120, 3990-3990 | 2.2 |
| 7 | Biomarkers of Bone Remodeling in Multiple Myeloma Patients to Tailor Bisphosphonate Therapy. *Blood*, **2012**, 120, 3965-3965 | 2.2 |
| 6 | Combinational Therapy of Lenalidomide with Activin A Neutralizing Antibody; Preclinical Rationale for a Novel Anti-Myeloma Strategy. *Blood*, **2012**, 120, 1871-1871 | 2.2 |
| 5 | Rational Combination Treatment of a Novel Selective mTOR Kinase Inhibitor AZD8055 with IGF-1R Inhibitors in Multiple Myeloma. *Blood*, **2012**, 120, 4023-4023 | 2.2 |
| 4 | AVL-292, a Bruton's Tyrosine Kinase Inhibitor Impacts Bone Resorption by Abrogating Osteoclast Sealing Zone Formation in Multiple Myeloma. *Blood*, **2012**, 120, 1822-1822 | 2.2 |
| 3 | Role Of Decorin In Multiple Myeloma (MM) Bone Marrow Microenvironment. *Blood*, **2013**, 122, 1851-1851 | 2.2 |
| 2 | Perceptions of prognosis in caregivers of multiple myeloma (MM) patients.. *Journal of Clinical Oncology*, **2021**, 39, 12082-12082 | 2.2 |
| 1 | Treatment of Patients in First or Second Relapse **2018**, 77-102 | |